Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. 

The first study of certolizumab pegol in combination with methotrexate in DMARD-naïve early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. 

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. 

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumor necrosis factor exposure. 

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. 

Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. 

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. 

Rheumatoid arthritis secondary nonresponders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. 

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.